AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02168465 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: teaching self-management of an intermittent catheter
Description: Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
Study NCT04163419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 10 mg SC
Study NCT01072695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg BID x 28 days
Study NCT04163419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanezumab
Description: Tanezumab 10 mg SC
Study NCT01072695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200 mg/day given BID
Study NCT01072695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 ug q week
Study NCT05190120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
Study NCT04163419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg SC
Study NCT00471237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret
Description: 100mg, 200mg, 300mg, 400mg
Study NCT00471237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: PTH (1-34)
Study NCT00471237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Bisphosphonate
Study NCT03061162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulsed low dose rate radiation therapy
Description: Pulsed low dose rate 3-dimensional conformal radiation therapy
Study NCT05190120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block
Description: Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
Study NCT05190120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine
Study NCT05190120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.
Study NCT01096017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler®
Description: 0.4 mg, inhalation, single dose
Study NCT01096017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI
Description: 200 μg, inhalation, single dose
Study NCT01096017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pMDI placebo pMDI
Description: Placebo pMDI 2 inhalations
Study NCT03729531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vein harvesting technique
Description: Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
Study NCT03729531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch vein harvesting technique
Description: The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
Study NCT02347748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-procedure script
Description: Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
Study NCT02347748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-extubation script
Description: Patients will be read a comfort talk script before extubation
Study NCT02347748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading 2 scripts
Description: Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation
Study NCT03214003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB
Description: patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
Study NCT03214003 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
Study NCT01096017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Turbuhaler®
Description: Placebo Turbuhaler 1 inhalation
Study NCT02009072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutureless and glue free limbal conjunctival autograft
Description: Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
Study NCT02009072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutured limbal conjunctival autograft
Description: Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
Study NCT03134001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patients receiving oral analgesics via the PCoA™ Acute
Description: PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
Study NCT02059265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02059265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01699061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: 3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
Study NCT01699061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered with a meal twice a day on Day 1
Study NCT03110367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Reframing Intervention
Description: Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
Study NCT03110367 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Group
Description: Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
Study NCT02728141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
Study NCT02728141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
Study NCT00912431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 administered on Day 1 of Period 1
Study NCT00912431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-126 administered on Day 1 of Period 2
Study NCT02377674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Graft, Model COR-VG-001
Description: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
Study NCT01881867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Given SC
Study NCT01881867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01958944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Study NCT03348306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain and cardiac MRI in one time with gadolinium injection.
Study NCT03348306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A blood sampling is also collected for hematocrit measure.
Study NCT05125640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
Description: Orally, with 240 mL of water at dosing in sitting position
Study NCT05125640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Description: Orally, with 240 mL of water at dosing in sitting position
Study NCT02531048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations on lower limbs
Description: 20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
Study NCT02531048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations cervical
Description: 15 laser stimulations cervical areas below the ears.
Study NCT04528719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT03314064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
Study NCT03088488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fasting venous blood samples
Study NCT03433417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera truSculpt
Description: One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
Study NCT04320784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
Study NCT04320784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
Study NCT03627728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib/placebo
Study NCT03627728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: regorafenib/placebo
Study NCT04126291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of whiteboard videos
Description: Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
Study NCT02420028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of OptiVein IV catheter
Description: Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
Study NCT02420028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of Vasofix Certo IV catheter
Description: Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
Study NCT04122573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
Study NCT04122573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography of aorta
Description: Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
Study NCT04122573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography of pulmonary arteries.
Description: Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
Study NCT04122573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
Study NCT04122573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin
Description: Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
Study NCT00847275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exclusive nephrology follow-up
Description: 250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring.
Study NCT00847275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric follow-up
Description: 250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status.
Study NCT00443183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Description: The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
Study NCT00443183 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Discharge Instructions
Description: Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
Study NCT02847793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze training
Description: Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
Study NCT02847793 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
Study NCT00515827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: 400 mg tablet taken orally twice daily
Study NCT00515827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 400 mg placebo tablet taken orally twice daily
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
Study NCT05248581 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: living donor liver transplantation
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Inj. Paracetamol 1 gm IV at the time of induction
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Inj. Propofol 2- 2.5 mg/kg will be given for induction
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Inj fentanyl 1.5mg/kg will be given at the time of induction.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Study NCT01220921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Discectomy
Description: Microsurgical removal of disc that is compressing a nerve root
Study NCT01220921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-level lumbar fusion
Description: pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
Study NCT02501642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concussion Coach
Description: smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
Study NCT02501642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT01303159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic bipolar radiofrequency probe (ENDOHPB)
Description: EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
Study NCT02586727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept
Description: This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
Study NCT02070718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Kappa Agonist
Study NCT02070718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half Dose Kappa Agonist
Study NCT02070718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01610726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced versus conventional recovery in colorectal surgery
Description: Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT00131027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin